The COVID-19 pandemic and the use of MS disease-modifying therapies
Top Cited Papers
- 1 April 2020
- journal article
- editorial
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 39, 102073
- https://doi.org/10.1016/j.msard.2020.102073
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumabMultiple Sclerosis and Related Disorders, 2016
- Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosisNeurology, 2015
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapyMultiple Sclerosis Journal, 2013
- Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated PatientsClinical Infectious Diseases, 2013
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) studyMultiple Sclerosis Journal, 2011
- Cell Adhesion AntagonistsBioDrugs, 2008
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- Detection of Coronavirus in the Central Nervous System of a Child With Acute Disseminated EncephalomyelitisPediatrics, 2004
- Natalizumab for Active Crohn's DiseaseThe New England Journal of Medicine, 2003